Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Employees - 528,
CEO - Mr. William J. Sibold,
Sector - Healthcare,
Country - US,
Market Cap - 7.22B
Altman ZScore(max is 10): 12.71, Piotroski Score(max is 10): 4, Working Capital: $863650000, Total Assets: $1042247000, Retained Earnings: $-1802182000, EBIT: -451221000, Total Liabilities: $287864000, Revenue: $180133000
AryaFin Target Price - $156.42 - Current Price $327.10 - Analyst Target Price $412.62
| Ticker | MDGL |
| Index | RUT |
| Curent Price | 327.10 |
| Change | -2.24% |
| Market Cap | 7.22B |
| Average Volume | 404.21K |
| Income | -465.89M |
| Sales | 180.13M |
| Book Value/Share | 34.28 |
| Cash/Share | 42.18 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 528 |
| Moving Avg 20days | -2.34% |
| Moving Avg 50days | -2.07% |
| Moving Avg 200days | 13.62% |
| Shares Outstanding | 22.00M |
| Earnings Date | Feb 26 BMO |
| Inst. Ownership | 104.00% |
| Price/Earnings | - |
| Forwad P/E | 196.34 |
| PE Growth | - |
| Price/Sales | 40.10 |
| Price/Book | 9.54 |
| Price/Cash | 7.76 |
| Price/FCF | - |
| Quick Ratio | 5.90 |
| Current Ratio | 6.10 |
| Debt/Equity | 0.16 |
| Return on Assets | -55.37% |
| Return on Equity | -80.35% |
| Return on Investment | -53.37% |
| Gross Margin | 95.93% |
| Ops Margin | -276.39% |
| Profit Margin | -258.64% |
| RSI | 47.08 |
| BETA(β) | -0.93 |
| From 52week Low | 73.07% |
| From 52week High | -13.34% |
| EPS | -22.11 |
| EPS next Year | 1.67 |
| EPS next Qtr | -3.74 |
| EPS this Year | 40.90% |
| EPS next 5 Year | - |
| EPS past 5 Year | -32.06% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | -10.89% |
| Sales Y/Y | - |
| EPS Q/Q | 52.28% |
| Sales Q/Q | - |
| Sales Surprise | 4.27% |
| EPS Surprise | 30.86% |
| ATR(14) | 16.34 |
| Perf Week | -3.02% |
| Perf Month | -5.81% |
| Perf Quarter | 6.01% |
| Perf Year | 33.78% |
| Perf YTD | 6.01% |
| Target Price | 412.62 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer